| abstract |
Human receptor selective atrial natriuretic factor variants containing vario us substitutions, especially G16R, show equal potency an d binding affinity for the human A-receptor but have decreased affinity for th e human clearance or C-receptor. These ANF variants hav e natriuretic, diuretic and vasorelaxant activity but have increased metaboli c stability, making them suitable for treating congestiv e heart failure, acute kidney failure and renal hypertension. |